AstraZeneca Pharma India to sell Meronem drug for a month more

Shital Jibhe / 28 Jul 2017

AstraZeneca Pharma India to sell Meronem drug for a month more

AstraZeneca Pharma India has received one month extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India, granted due to delay in the divestment of AstraZeneca’s global rights to Meronem.

AstraZeneca Pharma India has received one month extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India, granted due to delay in the divestment of AstraZeneca’s global rights to Meronem. 
 
It has extended the date of withdrawal of Meronem from July 31, 2017 to August 31, 2017.
 
In August last year, AstraZeneca Pharma India had announced that it will stop selling anti-bacterial drug Meronem in India following a global deal by its parent AstraZeneca UK to sell its small molecule antibiotics business to Pfizer Inc.
 
Meronem is used for the treatment of serious infections in hospitalised patients and the product has generated 18% total turnover of the firm in FY16.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.